retinal ganglion cell survival
Recently Published Documents


TOTAL DOCUMENTS

127
(FIVE YEARS 17)

H-INDEX

29
(FIVE YEARS 3)

2021 ◽  
Vol 10 (10) ◽  
pp. 16
Author(s):  
Anat Nitzan ◽  
Miriam Corredor-Sanchez ◽  
Ronit Galron ◽  
Limor Nahary ◽  
Mary Safrin ◽  
...  

2021 ◽  
pp. 136197
Author(s):  
Érica Camila Ferreira ◽  
Amanda Candida da Rocha Oliveira ◽  
Carlos Gustavo Garcia ◽  
Marcelo Cossenza ◽  
Cassiano Felippe Gonçalves de Albuquerque ◽  
...  

Nutrients ◽  
2021 ◽  
Vol 13 (6) ◽  
pp. 1949
Author(s):  
Drake W. Lem ◽  
Dennis L. Gierhart ◽  
Pinakin Gunvant Davey

Primary open-angle glaucoma (POAG) remains a leading cause of irreversible blindness globally. Recent evidence further substantiates sustained oxidative stress, and compromised antioxidant defenses are key drivers in the onset of glaucomatous neurodegeneration. Overwhelming oxidative injury is likely attributed to compounding mitochondrial dysfunction that worsens with age-related processes, causing aberrant formation of free radical species. Thus, a compromised systemic antioxidant capacity exacerbates further oxidative insult in glaucoma, leading to apoptosis, neuroinflammation, and subsequent tissue injury. The purpose of this systematic review is to investigate the neuroprotective benefits of the macular carotenoids lutein, zeaxanthin, and meso-zeaxanthin on glaucomatous neurodegeneration for the purpose of adjunctive nutraceutical treatment in glaucoma. A comprehensive literature search was conducted in three databases (PubMed, Cochrane Library, and Web of Science) and 20 records were identified for screening. Lutein demonstrated enhanced neuroprotection on retinal ganglion cell survival and preserved synaptic activity. In clinical studies, a protective trend was seen with greater dietary consumption of carotenoids and risk of glaucoma, while greater carotenoid levels in macular pigment were largely associated with improved visual performance in glaucomatous eyes. The data suggest that carotenoid vitamin therapy exerts synergic neuroprotective benefits and has the capacity to serve adjunctive therapy in the management of glaucoma.


Author(s):  
Tamiris Gago Colares ◽  
Camila Saggioro de Figueiredo ◽  
Lucienne de Oliveira Jesus Souza ◽  
Aline Araujo dos Santos ◽  
Elizabeth Giestal-de-Araujo

PLoS ONE ◽  
2021 ◽  
Vol 16 (1) ◽  
pp. e0243862
Author(s):  
Keirnan Willett ◽  
Reas S. Khan ◽  
Kimberly Dine ◽  
Howard Wessel ◽  
Ziv Z. Kirshner ◽  
...  

ST266 is the biological secretome of cultured Amnion-derived Multipotent Progenitor cells containing multiple growth factors and cytokines. While intranasally-administered ST266 improves the phenotype in experimental optic neuritis, specific ST266 components mediating these effects are not known. We compared the effects of ST266 with and without removal of large molecular weight proteins both in vitro and in the multiple sclerosis model experimental autoimmune encephalomyelitis (EAE) in C57BL/6J mice. Mice were treated daily with intranasal vehicle, ST266 or lower molecular weight fraction of ST266. Retinal ganglion cells were counted in isolated retinas, and optic nerves were assessed for inflammation and demyelination. ST266 treatment significantly improved retinal ganglion cell survival and reduced optic nerve demyelination in EAE mice. The lower molecular weight ST266 fraction significantly improved optic nerve demyelination, but only showed a trend towards improved retinal ganglion cell survival. ST266 fractions below 50kDa increased Schwann cell proliferation in vitro, but were less effective than non-fractionated ST266. Demyelination attenuation was partially associated with the lower molecular weight ST266 fraction, but removal of higher molecular weight biomolecules from ST266 diminishes its neuroprotective effects, suggesting at least some high molecular weight proteins play a role in ST266-mediated neuroprotection.


2021 ◽  
Vol 16 (6) ◽  
pp. 1121
Author(s):  
Ling-Ping Cen ◽  
Jia-Jian Liang ◽  
Yu-Fen Liu ◽  
TszKin Ng ◽  
Ci-Yan Xu ◽  
...  

2020 ◽  
Author(s):  
Raoul Torero-Ibad ◽  
Nicole Quenech’du ◽  
Alain Prochiantz ◽  
Kenneth L. Moya

AbstractRetinal ganglion cell axons provide the only link between the light sensitive and photon transducing neural retina and visual centers of the brain. Retinal ganglion cell axon degeneration occurs in a number of blinding diseases and the ability to stimulate axon regeneration from surviving ganglion cells could provide the anatomic substrate for restoration of vision. OTX2 is a homeoprotein transcription factor expressed in the retina and previous studies showed that, in response to stress, exogenous OTX2 increases the in vitro and in vivo survival of retinal ganglion cells. The present results show that, in addition to promoting adult retinal ganglion cell survival, OTX2 also stimulates the regeneration of their axons in vitro and in vivo. This dual activity of OTX2 on retinal ganglion cell survival and regeneration is of potential interest for degenerative diseases affecting this cell type.


Sign in / Sign up

Export Citation Format

Share Document